ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER

Information

  • Research Project
  • 9440351
  • ApplicationId
    9440351
  • Core Project Number
    U10CA180827
  • Full Project Number
    5U10CA180827-05
  • Serial Number
    180827
  • FOA Number
    RFA-CA-12-012
  • Sub Project Id
  • Project Start Date
    4/14/2014 - 10 years ago
  • Project End Date
    2/28/2019 - 5 years ago
  • Program Officer Name
    MOONEY, MARGARET M
  • Budget Start Date
    3/1/2018 - 6 years ago
  • Budget End Date
    2/28/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    05
  • Suffix
  • Award Notice Date
    2/26/2018 - 6 years ago

ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER

DESCRIPTION (provided by applicant): We propose to create an integrated Leukemia Translational Science Center (LTSC), which will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL), the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by E. Paietta, A. Melnick and R. Levine, who collectively lead the LLC, LTRL and LTB. Through these initiatives, they have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the New York Genome Center, which provides access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including patient specimens, the LTRL, access to the New York Genome Center, genomic and epigenetic profiling databases, and scientific support. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC expects to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U10
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    574685
  • Indirect Cost Amount
    25314
  • Total Cost
    599999
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:599999\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MONTEFIORE MEDICAL CENTER (BRONX, NY)
  • Organization Department
  • Organization DUNS
    041581026
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    104672490
  • Organization District
    UNITED STATES